Maravai Lifesciences Stock Gets IBD Stock Rating Upgrade

The IBD SmartSelect Composite Rating for Maravai Lifesciences (MRVI) increased from 94 to 97 Thursday morning, before the open.


The new rating shows the stock is outpacing 97% of all stocks when it comes to the most important stock-picking criteria. Winning stocks often have a 95 or higher rating in the early stages of a new price run, so that’s a good item to have on your checklist when looking for the best stocks to buy and watch.

Maravai Lifesciences is now trading just above the buy range after rising 39% from a 45.89 buy point in a cup without handle. It has gapped down after two recent secondary offerings. Watch for a new pattern to offer a new entry point should it contine the recent gains.

See How IBD Helps You Make More Money In Stocks


One weak spot is the company’s 65 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it’s in the top 20% of all stocks.

Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.

Maravai Lifesciences stock posted a 4,300% rise in earnings for Q2. Sales growth increased 364%, up from 191% in the prior report. The company has now posted accelerating growth in each of the last four reports.

Maravai Lifesciences stock holds the No. 2 rank among its peers in the Medical-Biomed/Biotech industry group. Regeneron Pharmaceutical (REGN) is the No. 1-ranked stock within the group.


Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros
MarketSmith’s Tools Can Help The Individual Investor
Profit From Short-Term Trends With SwingTrader
Get Timely Buy & Sell Alerts With IBD Leaderboard
Find The Best Long-Term Investments With IBD Long-Term Leaders


Most Related Links :
usnewsmail Governmental News Finance News

Source link

Back to top button